FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Cogentin Not Withdrawn Due to Safety/Efficacy

Federal Register notice: FDA determines that Akorns Cogentin (benztropine mesylate) Injection (1 mg/1 mL) was not withdrawn due to safety or effective...

latest-news-card-1
Human Drugs

CDER Quality Office Reorganizing Next Year

CDER announces a reorganization of the Office of Pharmaceutical Quality effective 1/14/2024.

latest-news-card-1
Medical Devices

BD Mesh Products Alert on Breast Surgery

FDA tells healthcare providers about labeling updates to Becton Dickinsons (BD) Phasix and GalaFlex mesh products that discourage breast surgery use.

latest-news-card-1
Medical Devices

FDA Approves Recor Paradise System

FDA approves a PMA for the Recor Medical Paradise renal denervation system to treat hypertension.

latest-news-card-1
Medical Devices

CareFusion Recalls Alaris Pump Module

Becton Dickinsons CareFusion unit recalls its Alaris Patient Controlled Analgesia infusion pump module 8120 because the compatible syringes labeling c...

latest-news-card-1
Human Drugs

Dont Approve Amryts Filsuvez NDA: Petition

A Lassman Law petition filed for an unidentified client asks FDA not to approve an Amryt NDA for Filsuvez to treat cutaneous manifestations of junctio...

latest-news-card-1
Federal Register

Compliance Delay on Cosmetic Registration

Federal Register notice: FDA makes available a guidance entitled Compliance Policy for Cosmetic Product Facility Registration and Cosmetic Product Lis...

latest-news-card-1
Human Drugs

Former Reviewer McGarry Joins Greenleaf Health

Former FDA reviewer Sarah McGarry joins consulting firm Greenleaf Health as senior vice president of drug and biological products.

latest-news-card-1
Marketing

Rexulti Ads False and Misleading: OPDP

The CDER Office of Prescription Drug Promotion says two Otsuka Rexulti ads contain misleading presentations of the drugs efficacy.

latest-news-card-1
Human Drugs

Lilly Obesity Drug Gains FDA Approval

FDA approves an Eli Lilly NDA for Zepbound (tirzepatide) subcutaneous injection for chronic weight management in obese adults who are on a reduced cal...